###### Strengths and limitations of this study

-   This is a population-based study, therefore we tried to do a real estimation of incidence and mortality among patients with primary Sjögren\'s Syndrome (pSS) and to report the incidence of interstitial lung disease (ILD) among patients with pSS and what is its impact on pSS morality.

-   Attention to the occurrence of, and the improved management of, ILD in patients with pSS may contribute to the reduction of disease burden.

-   The major concern is related to the chart review-based diagnosis; our estimates could not reflect the full extent of ILD in this population. The limited information on tests of lung disease available for each patient inherent to a retrospective study and the unavailability of some information due to time trend effects may lead to a misclassification bias.

-   Moreover, an overestimation of lung involvement in participants with pSS compared to those without pSS (surveillance bias) could be present. pSS incidence seems to be almost the same as was reported in a previous study conducted among Olmsted County Minnesota population.Survival among patients with pSS and general population does not differ substantially.Patients with pSS who have ILD most likely have an increased premature mortality.

Introduction {#s1}
============

Sjögren\'s syndrome (SS) is a chronic autoimmune and systemic inflammatory disease that affects exocrine and extraglandular tissues.[@R1] It is known to occur alone (primary) or in association with other autoimmune disease states.

A very few studies describe the epidemiology of primary SS (pSS).

The published studies of pSS in the general population report highly heterogeneous results. The wide-ranging prevalence estimates in adults varied from 0.098% to 3.59% while the incidence ranged from 3.9 to 5.3/100 000 population.[@R2] [@R3] This wide variation is due to the diverse populations using a restricted age range,[@R4] low sample size[@R5] or low follow-up rate.[@R6] The studies of SS also have used a variety of classification criteria leading to difficulties when trying to compare the results.

Extraglandular manifestations of pSS include a broad spectrum of lung disease. The reported frequency of pulmonary involvement in pSS varies widely ranging from 8% to 75% depending on the detection method employed, and consists of various forms of airways disease (bronchiectasis, obstructive airways disease) and interstitial lung disease (ILD).[@R7] Lymphocytic interstitial pneumonia is well defined in patients with pSS,[@R8] but there is relatively little information regarding other ILD patterns occurring in pSS in terms of frequency and risk factors.

Extra-articular disease manifestations, including various forms of lung disease, are common in pSS and may be linked to an increased mortality.[@R9] Asymptomatic pulmonary changes are present in a majority of patients, but their impact on the disease course, mortality and quality of life remains unclear.

Most studies have concentrated on ILD in consecutive samples of patients with pSS in academic centres.[@R7] [@R9; @R10; @R11; @R12] Consequently, a little is known about the incidence of the full spectrum of respiratory system involvement in a representative sample of patients with pSS from a population-based cohort. Previous studies that examined the incidence or prevalence of pSS-associated lung disease have differed widely in their estimates. This wide variance appears to be due to different diagnostic modalities used to detect the disease, the changed criteria for the classification of SS, previous failure to separate out patients with primary or secondary SS and referral bias in studies originating from large academic centres.

In non-population-based studies, pulmonary changes can be documented in a majority of patients with pSS[@R10; @R11; @R12] and clinically overt ILD is present in 6--94% in early and longstanding pSS.[@R7] [@R10; @R11; @R12] There are no population-based estimates of the incidence of pSS and the incidence of pSS-associated ILD. Here, we report on the incidence, and impact on survival of ILD among Olmsted County, Minnesota residents with pSS.

Patients and methods {#s2}
====================

This was a retrospective medical record review to investigate the ILD in patients with pSS in Olmsted County, Minnesota, diagnosed during the 45 years period from 1 January 1976 to 31 December 2005 and then followed until death, migration or 31 December 2011.

The population of Olmsted County, Minnesota is well suited for investigation of long-term outcomes of patients with pSS. A medical records linkage system, the Rochester Epidemiology Project (REP), allows a ready access to the complete (inpatient and outpatient) records from all healthcare providers for the local population, including the Mayo Clinic and its affiliated hospitals, the Olmsted Medical Center and its affiliated community hospital, local nursing homes and a few private practitioners. The potential of this data system for population-based research has been previously described.[@R13] [@R14] This system ensures a virtually complete clinical and vital status information on all clinically recognised cases of pSS among Olmsted County residents.

Ascertainment of pSS cases {#s2a}
--------------------------

Using this data resource, a population-based incidence cohort of all cases of pSS, first diagnosed between 1 January 1976 and 31 December 2005, among Olmsted County, Minnesota residents ≥18 years of age was assembled. The cohort initially assembled between 1976 and 1992 was enriched adding new patients with pSS diagnosed between 1993 and 2005.[@R3] All cases fulfilled the 2002 American-European Consensus Group (AECG) diagnostic criteria for pSS.[@R15] Incidence date is defined as the first date of fulfilment of four of the six AECG diagnostic criteria.

All participants were followed up longitudinally through their complete medical records beginning at age 18 (or date of migration to Olmsted County for those who became residents after age 18) and continuing until death, migration from Olmsted County or 31 December 2011.

Data collection {#s2b}
---------------

The original and complete medical records of each patient with pSS were reviewed by CN and AJJ. Uncertainties regarding the classification of pSS, presence and type of pulmonary disease and underlying disease were adjudicated by JHR and/or ELM.

We abstracted demographic data (date of birth and gender), smoking status at pSS incidence date (never smoked/former smoker/current smoker) and smoking status at diagnosis of lung disease (never smoked/former smoker/current smoker). The date of last follow-up as well as the status at the last follow-up (dead/alive) was recorded.

SS features were abstracted, and they included time variables (year of symptom onset, year of diagnosis according to the AECG diagnostic criteria),[@R15] ocular and oral gland involvement (clinical judgement, Schirmer test, salivary glands biopsy and salivary scintigraphy) and laboratory features (rheumatoid factor (RF), antinuclear antibody (ANA), anti-SSA, anti-SSB and IgG level).

Definition and ascertainment of ILD {#s2c}
-----------------------------------

The ascertainment of ILD was based on clinical data, pulmonary function test results (total lung capacity, forced vital capacity, forced expiratory volume in 1 s, diffusing capacity for carbon monoxide, SaO~2~, at rest and with exercise), radiological studies (chest radiographs, CT), bronchoalveolar lavage and lung biopsy. The criteria used to classify ILD were validated in a previous study, and are given in [table 1](#BMJOPEN2013003569TB1){ref-type="table"}.[@R16]

###### 

Classification criteria for ILD in primary Sjögren\'s syndrome

  -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Probable ILD   Chest radiograph or CT described as 'fibrosis' or 'consistent with ILD or parenchymal lung disease'\
                 or\
                 Physician\'s diagnosis of 'interstitial lung disease', 'pulmonary fibrosis', 'interstitial pneumonia', etc

  Definite ILD   Diagnosis of ILD by a pulmonologist, based on chest radiograph/high resolution chest CT and pulmonary function testing (restrictive ventilatory pattern or reduced DLCO)\
                 or\
                 Lung biopsy (bronchoscopic or surgical)
  -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DLCO, diffusing capacity for carbon monoxide; ILD, interstitial lung disease.

Statistical analysis {#s2d}
--------------------

Descriptive statistics (means, medians, proportions, etc) were used to summarise the data. Comparison of patient characteristics between time periods was performed using χ^2^ tests for categorical characteristics and Wilcoxon rank sum tests for continuous characteristics.

The overall incidence rates were age-adjusted and/or sex-adjusted to the 2000 white population of the USA. Age-specific and sex-specific incidence rates were calculated by using the number of incident cases as the numerator and population estimates based on decennial census counts as the denominator, with linear interpolation used to estimate population size for intercensal years.[@R17] In order to compute 95% CI for incidence rates, it was assumed that the number of incident cases followed a Poisson distribution. Trends in incidence rates were examined using Poisson regression methods using smoothing splines for age and calendar year.[@R18]

The percentage of patients with pSS with respiratory system involvement at pSS incidence date was computed. Those with respiratory system involvement at pSS incidence date were excluded from the analysis of cumulative incidence. The cumulative incidence of respiratory system involvement (and subtypes) was estimated using product-limit life table methods, accounting for the competing risk of death.[@R19]

Product-limit life table methods were used to estimate the survival of patients with pSS. The expected number of deaths was determined from the National Center for Health Statistics life tables for the USA population, according to the age, sex and calendar year of the pSS cohort.[@R20] A standardised mortality ratio (SMR) was estimated by dividing the observed number of deaths by the expected number of deaths. Ninety-five per cent CIs for the SMR were calculated assuming that the expected rates were fixed and the observed rates followed a Poisson distribution. A Cox model was used to examine the impact of respiratory system involvement on mortality with a time-dependent covariate indicating the development of respiratory system involvement (whereby patients were modelled as unexposed during the follow-up time prior to development of respiratory system involvement and were then modelled as exposed following the development of respiratory system involvement) and adjustment for age, sex and calendar year of diagnosis of pSS. Statistical analysis was performed using SAS software (V.9.3, SAS Institute Inc, Cary, North Carolina, USA).

Results {#s3}
=======

We identified 105 patients with incident pSS with a mean age at pSS diagnosis of 58.1 years (range 23--95); 91% were women. Demographic data and general characteristics of the study population are reported in [tables 2](#BMJOPEN2013003569TB2){ref-type="table"}[](#BMJOPEN2013003569TB3){ref-type="table"}--[4](#BMJOPEN2013003569TB4){ref-type="table"}.

###### 

Characteristics of 105 patients with primary Sjögren\'s syndrome

                               1976--1992 (n=50)   1993--2005 (n=55)   Total (n=105)   p Value                                   
  ---------------------------- ------------------- ------------------- --------------- ----------------- ----- ----------------- -------
  Sex, female (%)              50                  48 (96)             55              48 (87)           105   96 (91)           0.11
  Age at incidence, years      50                  57.5 (23--95)       55              59.2 (26--86)     105   59.2 (23--95)     0.96
  Length of follow-up, years   50                  17.2 (0.4--34.2)    55              7.7 (0.1--17.3)   105   9.2 (0.1--34.2)   --
  Smoking                                                                                                                        
   Never                       44                  29 (66)             52              27 (52)           96    56 (58)           0.020
   Current                     8 (18)              4 (8)               4 (8)                                                     
   Former                      7 (16)              21 (40)             21 (40)                                                   

N is the number of patients with parameter reported in the medical records.

\*Value is N (%) or median (minimum, maximum). Percentages are calculated based on available N.

###### 

Laboratory assessment of 105 patients with primary Sjögren\'s syndrome

                                         1976--1992 (n=50)   1993--2005 (n=55)   Total (n=105)   p Value                  
  -------------------------------------- ------------------- ------------------- --------------- --------- ---- --------- -------
  Rheumatoid factor, positive (%)        37                  14 (38)             45              32 (71)   82   46 (56)   0.002
  Antinuclear antibodies, positive (%)   37                  20 (54)             52              42 (81)   89   62 (70)   0.007
  Anti-SSA, positive (%)                 17                  7 (41)              48              38 (79)   65   45 (69)   0.004
  Anti-SSB, positive (%)                 18                  6 (33)              48              30 (63)   66   36 (55)   0.034
  Hypergammaglobulinaemia, present (%)   38                  16 (42)             44              26 (59)   82   42 (51)   0.12
  Histopathology, available (%)          0                   --                  6               3 (50)    6    3 (50)    --

N is the number of patients with parameter reported in the medical records.

\*Value is N (%) or median (minimum, maximum). Percentages are calculated based on available N.

###### 

Clinical characteristics of 105 patients with primary Sjögren\'s syndrome

                                       1976--1992 (n=50)   1993--2005 (n=55)   Total (n=105)   p Value                   
  ------------------------------------ ------------------- ------------------- --------------- --------- ----- --------- ------
  Ocular symptoms, present (%)         48                  45 (94)             54              52 (96)   102   97 (95)   0.55
  Oral symptoms, present (%)           45                  42 (93)             50              48 (96)   95    90 (95)   0.56
  Ocular signs, present (%)            30                  30 (100)            9               8 (89)    39    38 (90)   0.06
  Oral signs, present (%)              46                  3 (7)               1               0 (0)     47    3 (6)     --
  Ocular signs/symptoms, present (%)   48                  45 (94)             54              52 (96)   102   97 (95)   0.55
  Oral signs/symptoms, present (%)     49                  42 (86)             50              48 (96)   99    90 (91)   0.08

N is the number of patients with parameter reported in the medical records.

\*Value is N (%) or median (minimum, maximum). Percentages are calculated based on available N.

Considering the time periods, patients differ significantly with regard to laboratory evaluation: RF, ANA, anti-SSA and anti-SSB were significantly more frequently detected in the 1993--2005 time period compared with the 1976--1992 cohort. Among clinical features, ocular signs tended towards statistical significance in 1993--2005 period with a p value of 0.06.

The annual incidence of pSS was 5.1 (95% CI 4.1 to 6.1)/100 000 population, and increased with higher age at pSS diagnosis (18--44 years: 1.8/100 000 vs ≥75 years: 10.7/100 000; [table 5](#BMJOPEN2013003569TB5){ref-type="table"}). Female patients were more affected (8.7/100 000 population (95% CI 6.9 to 10.4)) compared with male patients (1.1/100 000 (95% CI 0.4 to 1.9; [table 5](#BMJOPEN2013003569TB5){ref-type="table"})).

###### 

Annual incidence of primary Sjögren\'s syndrome diagnosed between 1976 and 2005 in Olmsted County, Minnesota Residents ≥18 years of age, by sex and age group\*

  Age group        Male (n=9)   Female (n=96)       Total (N=105)                              
  ---------------- ------------ ------------------- --------------- -------------------- ----- -------------------
  18--44 years     3            0.5                 22              3.1                  25    1.8
  45--54 years     1            0.5                 20              10.6                 21    5.6
  55--64 years     0            0.0                 20              15.3                 20    7.9
  65--74 years     1            1.3                 21              21.8                 22    12.7
  ≥75 years        4            7.5                 13              12.3                 17    10.7
  Total (95% CI)   9            1.1 (0.4 to 1.9)†   96              8.7 (6.9 to 10.4)†   105   5.1 (4.1 to 6.1)‡

\*Values are the annual incidence rates (95% CI) per 100 000 population.

†Age adjusted to the 2000 US white population.

‡Age and sex adjusted to the 2000 US white population.

The overall incidence increased modestly during the study period (3.9 (95% CI 2.2 to 5.6)/100 000 population in 1976--1985; 5.0 (95% CI 3.3 to 6.7) in 1986--1995; and 5.9 (95% CI 4.2 to 7.6) in 1996--2005; linear trend p=0.06; [table 6](#BMJOPEN2013003569TB6){ref-type="table"} and [figure 1](#BMJOPEN2013003569F1){ref-type="fig"}).

###### 

Annual incidence of primary Sjögren\'s syndrome diagnosed between 1976 and 2005 by decade in Olmsted County, Minnesota residents ≥18 years of age, by sex and age group\*

  Age group    Male (n=9)   Female (n=96)       Total (N=105)                             
  ------------ ------------ ------------------- --------------- -------------------- ---- -------------------
  1976--1985   1            0.7 (0.0 to 2.2)†   20              6.8 (3.8 to 9.9)†    21   3.9 (2.2 to 5.6)‡
  1986--1995   1            0.6 (0.0 to 1.6)†   34              9.1 (6.0 to 12.2)†   35   5.0 (3.3 to 6.7)‡
  1996--2005   7            1.9 (0.4 to 3.3)†   42              9.5 (6.6 to 12.4)†   49   5.9 (4.2 to 7.6)‡

\*Values are the annual incidence rates (95% CI) per 100 000 population.

†Age adjusted to the 2000 US white population.

‡Age and sex adjusted to the 2000 US white population.

![Annual incidence of primary Sjögren\'s syndrome per 100 000 populations in residents of Olmsted County, Minnesota, 1976--2005. The broken line was calculated as a 3-year-centered moving average, and the solid line depicts trends in the incidence rates after adjustment for age and sex (linear trend p=0.06).](bmjopen2013003569f01){#BMJOPEN2013003569F1}

During a median follow-up of 9.2 years (1205 total person-years), 25 patients died. This was similar to the 29.5 expected deaths (SMR: 0.85, 95% CI 0.55 to 1.25), logrank p value=0.41 ([figure 2](#BMJOPEN2013003569F2){ref-type="fig"}).

![Survival in patients with primary Sjögren\'s (solid line) compared with the general population (dotted line; logrank p=0.41).](bmjopen2013003569f02){#BMJOPEN2013003569F2}

ILD in pSS {#s3a}
----------

Lung disease was present prior to the diagnosis of pSS in 12 patients and developed after diagnosis of pSS in 35 patients with a median follow-up time of 9.2 years (1205 total person-years). Among patients with pSS without prior ILD, the cumulative incidence of ILD in patients with pSS was 10% (±3%) at 1 year after diagnosis of pSS and increased to 20% (±4%) by 5 years, and 43% (±7%) by 15 years after pSS onset. The development of lung disease in pSS was associated with poor survival with an HR of 2.16 (95% CI 0.99 to 4.74) adjusted for age, sex and calendar year although this did not reach the statistical significance. ILD was identified as the most frequent type of lung disease detected at or after pSS diagnosis (53%) followed by emphysema (13%).

Discussion {#s4}
==========

We found that the annual incidence of pSS was 5.1 (95% CI 4.1 to 6.1)/100 000 population and increases with higher age at pSS diagnosis (18--44 years: 1.8/100 000 vs ≥75 years: 10.7/100 000). Comparison to existing epidemiological studies is complicated by differences in disease definition and classification criteria. Until now only three studies have evaluated the incidence of pSS in general population, reporting values from 3.9 to 5.3/100 000 population.[@R3] [@R21] [@R22]

We found that the incidence of pSS may have increased modestly during the study period with a linear trend p value of 0.06, although the overall trend is almost stable despite the differences among the diagnostic criteria occurring over the years. pSS has an incidence peak between 55 and 74 years of age with women more frequently affected than men.

The risk of death in patients with pSS in our study is similar to that in the general population (0.85; 95% CI 0.55 to 1.25). A prospective study conducted in Greece reported a higher risk of mortality in patients with pSS compared with that in the general population (SMR 2.07; 95% CI 1.03 to 3.71).[@R21] However, when patients with adverse predictors (low levels of C4, presence of mixed monoclonal cryoglobulins and purpura) were excluded the mortality rate was identical to the general population (SMR 1.02).[@R23]

Similar to our study, most other studies reported an SMR that range between 1.2 and 1.42 without reaching a statistical significance.[@R3] [@R24] [@R25; @R26; @R27] Therefore the survival of these patients is comparable with that of the general population.[@R28] [@R29]

Case findings was based on 2002 AECG criteria, used for this study since the cohort was assembled in two time periods, 1976--1992 and 1993--2005. Owing to the new 2012 published expert consensus approach for pSS classification criteria,[@R30] feature increased reliance on serological evaluation compared with the older criteria, we were concerned that our study would be affected by the time trend effects affecting classification and therefore used the AECG criteria. Nonetheless, clinical features important in classification have remained unchanged in the two time periods reported in [table 4](#BMJOPEN2013003569TB4){ref-type="table"}.

Lung involvement in pSS represents one of the most intriguing aspects of the disease. In this study, patients with pSS without prior ILD have a cumulative incidence of ILD of 10% (±3%) at 1 year after diagnosis of pSS, which increases to 20% (±4%) by 5 years after the onset of pSS. Patients who developed ILD prior to their pSS diagnosis were calculated apart from our primary analysis in order to avoid any incidence-prevalence bias. Therefore, the overall risk for individuals with pSS to be affected by ILD either prior or after their diagnosis of pSS will be somewhat higher than our estimate. In addition, patients with pSS have more frequent physician visits than the average patient in the population, and physicians may be more attuned to the possibility of lung disease in patients with pSS than in healthy people, leading to an overestimation of lung involvement in participants with pSS compared with those without pSS (surveillance bias).

In contrast to these population-based estimates, the existing literature on ILD and pSS is based on the studies of ILD prevalence in consecutive series of patients with pSS in the academic centres. In non-population-based studies, pulmonary changes can be documented in a majority of patients with pSS,[@R10; @R11; @R12] and clinically overt ILD is present in 6--94% of patients, in early and longstanding pSS.[@R7] [@R10; @R11; @R12] This wide variance appears to be due to different diagnostic modalities used to detect the disease, the changed criteria for the classification of SS, previous failure to separate out patients with primary or secondary SS and referral bias in studies originating from large academic centres.

Patients with pSS and ILD have a worse survival rate (HR 2.16; 95% CI 0.99 to 4.74). This is in contrast to a prospective cohort study which did not find increased all-cause mortality in patients with pSS compared with the general population.[@R24] In a retrospective study conducted at Mayo Clinic among 18 patients who underwent lung biopsies, seven patients (39%) died, including three deaths from acute exacerbation.[@R7]

Important limitations of our retrospective study approach should be acknowledged. Owing to the inherent limitations of a chart review-based diagnosis, it is likely that our estimates do not reflect the full extent of ILD in this population. The limited information on tests of lung disease (including radiographs, CT and pulmonary function testing) available for each patient inherent to a retrospective study and the unavailability of some information due to time trend effects (eg, CT became available in the 1970s) may lead to a misclassification bias. However, the use of rigorous criteria for ILD diagnosis established by the collaboration between an expert pulmonologist and rheumatologist should have reduced the possibility of this bias.

Our definition of ILD does represent a blend of many different types of parenchymal lung disease. Owing to the changes in availability of diagnostic tools such as CT over time as well as the evolution of definitions used to characterise ILD, reliable assignment of ILD subtypes for every patient according to the most recent American Thoracic Society consensus classification[@R31] was not possible.

In conclusion, the incidence of pSS, evaluated using the new ACR classification criteria for pSS, was similar to that reported in a previous study from the same population based on physician diagnosis. The incidence of pSS appears to be increasing in recent years. Our findings emphasise the high incidence of ILD among patients with pSS, and the adverse effect of this disease complication on survival. Patients with pSS should be carefully assessed for diagnosis and management of ILD in order to improve the detrimental survival experience.
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